Irinotecan vs non‐irinotecan‐containing regimens
Tumour response · people with advanced gastric cancer
Irinotecan may leads to higher tumour response compared with non‐irinotecan‐containing regimens (low certainty).
4 findings from 1 review
- OR 1.72 [1.24, 2.4]10 studies · 1266 participantsLow
- OR 1.53 [0.93, 2.5]6 studies · 756 participantsLow
- OR 2.18 [1.25, 3.8]3 studies · 345 participantsLow
Show 1 more finding
- OR 1.87 [0.89, 3.91]2 studies · 165 participantsVery low